You are here

In the News

April 29, 2016
The time is right for the FDA to reorganize in a stepwise, structural, disease-oriented manner to align its regulatory science with major advances in medicine, according to a panel at a Senate... Read more
April 29, 2016
Targeted immunotherapies have added an important new treatment approach to oncologists' armamentarium, especially for melanoma, lung cancer, and blood cancers. Cancer immunotherapy is considered such... Read more
April 26, 2016
Cancer patients have traditionally been treated based on where their tumors originate — lung tumors with treatments for lung cancer, breast tumors with therapies developed specifically for breast... Read more
April 25, 2016
“In order to take advantage of today’s advancements in science, drug development, and patient treatment, the U.S. Food and Drug Administration’s (FDA’s) structure needs reorganization to focus its... Read more
April 25, 2016
Executive SummaryProducts like Amgen's viral therapy for melanoma could benefit under proposals to replace FDA's modality-based organization with disease-specific centers. FDA's biologics center... Read more
April 21, 2016
Executive SummaryCommissioner Califf says review staff reorganization based on disease will go ahead regardless of what other headway VP Biden's initiative makes.Oncology product regulation at FDA... Read more
April 20, 2016
Today is a new day for cancer research, with the introduction of transformational immune-based therapies that have the potential to change patients' lives. Such potential means that everyone must... Read more
April 14, 2016
The FDA's breakthrough therapy designation has led to shorter drug development times and shorter FDA review times, industry experts said April 12 during a Senate briefing.Enacted in July 2012 as part... Read more
April 13, 2016
Parker Institute to Progress Cancer Immunotherapy ResearchFriends Proud to be Launch Partner for Initiative                     Los Angeles, CA, April 13, 2016 -  Friends of Cancer Research (Friends... Read more
April 9, 2016
Chair and founder of Friends of Cancer Research, Ellen Sigal, has been appointed to the National Cancer Institute's Blue Ribbon Panel that will advise the National Cancer Advisory Board on Vice... Read more

Pages